Former Editas CEO Bosley joins UK venture capital firm
Bio Pharma Dive
MAY 26, 2022
Bosley, who once led the CRISPR gene editing biotech, will become a venture partner at Advent Life Sciences, which backs a range of early-stage drug companies.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Bio Pharma Dive
MAY 26, 2022
Bosley, who once led the CRISPR gene editing biotech, will become a venture partner at Advent Life Sciences, which backs a range of early-stage drug companies.
pharmaphorum
JANUARY 13, 2025
Discover how data science and AI are set to revolutionise the life sciences industry by 2025, with a focus on mRNA technology and CRISPR gene editing. Stay ahead of the curve with these cutting-edge advancements.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 14, 2022
Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way. The PASTE gene editing technique was recently published in Nature Biotechnology.
XTalks
DECEMBER 20, 2023
As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.
XTalks
MAY 22, 2024
In this episode, Ayesha spoke with John Finn, PhD, Chief Scientific Officer at Tome Biosciences , a company developing programmable gene insertion (PGI) technology. PGI is a cutting-edge gene editing technology that allows for the insertion of large sequences of DNA with site-specific precision.
XTalks
DECEMBER 22, 2021
If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.
Drug Discovery Today
OCTOBER 27, 2022
27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
BioSpace
NOVEMBER 1, 2020
Horizon Discovery Group brings new gene editing and gene modulation tools to PerkinElmer’s expanding life sciences portfolio.
BioSpace
NOVEMBER 15, 2021
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
BioSpace
OCTOBER 14, 2021
Read about TFF Pharmaceuticals and Augmenta Bioworks' dry powder COVID-19 antibody formula, the world's first gene editing clinical trial for PKU, Bayer's COVID-19 vaccine and other key developments in life sciences research.
XTalks
DECEMBER 29, 2022
The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
pharmaphorum
OCTOBER 7, 2020
Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. In 2011, Emmanuelle Charpentier and Jennifer Doudna had no idea that their first meeting, in a café in Puerto Rico, would be life-changing.
pharmaphorum
DECEMBER 14, 2022
Healthcare commercial services agency Eversana announced that Sy Pretorius (as pictured), a 25-year life sciences veteran, will join the company as chief operating officer and president of outsourced solutions. November saw the launch of a new private equity team in life sciences at J.P. Eversana taps new COO.
XTalks
AUGUST 29, 2022
Now a common gene editing tool, the popularity of the CRISPR-Cas9 system has increased over the past decade. CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome.
Pharmaceutical Technology
FEBRUARY 13, 2023
This is particularly the case for pediatric forms of epilepsy where gene editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are becoming more important, says Ferraro. SK Life Science is a subsidiary of SK, a South Korean holding company.
Pharmaceutical Technology
MARCH 1, 2023
Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.
Pharmaceutical Technology
MARCH 1, 2023
Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.
Drug Discovery Today
OCTOBER 27, 2022
27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
XTalks
MAY 12, 2021
Subscribe to the Xtalks Life Science Podcast to never miss a new episode. New Study Looks at Effects of ADHD Drugs in Preschoolers. The weekly podcast is available for streaming every Wednesday on Spotify , Apple Music and wherever you stream your podcasts.
pharmaphorum
NOVEMBER 23, 2021
It is also close to Cambridge University, seen as one of the world’s leading life sciences research centres, as well as the city’s Addenbrookes Hospital, an important centre for clinical trials in the National Health Service.
XTalks
JANUARY 26, 2024
Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. The ongoing innovations in CRISPR/Cas9 gene-editing, CAR T-cell therapies and AI in oncology present hope.
BioTech 365
OCTOBER 22, 2020
-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & an immuno-centric discovery life science company with a … Continue reading →
XTalks
OCTOBER 12, 2021
Ritu Chakravarti, assistant professor in the UToledo College of Medicine and Life Sciences, and the paper’s lead author, was investigating 14-3-3? They found that removal of the protein using gene editing technology led to severe early onset arthritis as well as bone loss in two rat models.
pharmaphorum
APRIL 21, 2021
Darrin discusses the story behind Mogrify’s technology and his career journey with gene editing company Horizon Discovery Group Plc which was acquired by PerkinElmer in 2020.
XTalks
FEBRUARY 8, 2024
This day, observed globally on February 11, underscores the critical role of gender equality in science, spotlighting the achievements of women pioneers in the field while also emphasizing the need to encourage and support the next generation of female scientists.
XTalks
OCTOBER 20, 2023
Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
pharmaphorum
AUGUST 31, 2022
One area of the gene therapy space that could become a major treatment modality is CRISPR technology. The key to why this technology could become central to gene editing is due to the specificity with which it can edit DNA and that it is also a relatively cheap process, compared with existing technologies.
XTalks
SEPTEMBER 20, 2024
Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality. Its therapeutic pipeline targets unmet needs in oncology and autoimmune disease.
XTalks
MAY 4, 2021
Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences. The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing.
pharmaphorum
JULY 1, 2021
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, says Debiopharm’s Tanja Dowe.
XTalks
JANUARY 4, 2024
Gene therapy approvals for rare blood disorders like sickle cell disease and beta thalassemia have been gaining traction lately, with two significant approvals in sickle cell disease recently — CRISPR Therapeutics and Vertex Pharmaceuticals’ CRISPR gene editing drug Casgevy (exa-cel) and bluebird bio’s viral vector therapy Lyfgenia (lovo-cel).
XTalks
MARCH 28, 2024
Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth Council – Xtalks Life Science Podcast Ep. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.
XTalks
NOVEMBER 3, 2023
CRISPR works as genetic scissors to edit parts of the genome. The CRISPR-Cas9 gene editing system was first discovered to be endogenous in bacteria. Given the system’s powerful ability to make cuts in genes in a precise manner, the system is being leveraged in gene therapies.
XTalks
JULY 14, 2022
CRISPR-Cas9 gene editing was used to simultaneously perturb thousands of genes by targeting specific points of genetic code.
XTalks
NOVEMBER 30, 2023
These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV.
Delveinsight
JANUARY 14, 2021
Altitude Life Science Ventures, and the second SoftBank Vision Fund, with participation from the Qatari Investment Authority and other undisclosed investors. Verve Therapeutics has an aim to bring one-and-done gene editing treatments to heart disease. The round was led by Alaska Permanent Fund Corp.,
The Pharma Data
JANUARY 12, 2021
In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer. The platform is already bearing fruit.
XTalks
SEPTEMBER 4, 2024
The HELIOS-B study’s findings are timely as new gene-editing therapies, like the one being studied in MedStar Health’s Phase III MAGNITUDE trial for ATTR-CM, are also being explored. The MAGNITUDE trial uses CRISPR/Cas9 technology to target the genetic source of the disease, potentially offering a one-time treatment.
XTalks
DECEMBER 13, 2023
Casgevy’s approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the US. The process leading up to injection includes blood transfusions over three to four months, extraction of stem cells and chemotherapy to destroy the bone marrow to ensure there are no remaining defective stem cells.
XTalks
MAY 4, 2021
Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences. The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing.
XTalks
AUGUST 2, 2023
With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. 21) Merck KGaA By: Ayesha Rashid, Ph.D.
The Pharma Data
MARCH 11, 2021
Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”
The Pharma Data
DECEMBER 28, 2020
Most recently, these companies include: Fibrocor Therapeutics; Encyte Therapeutics (acquired by Zealand Pharma A/S); and Notch Therapeutics, a biotechnology company focused on gene-edited T cell therapies, which has a strategic partnership with Allogene Therapeutics. Dr. Hofstein received his B.Sc. Lesley Russell , MB.Ch.B,
XTalks
FEBRUARY 27, 2024
There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content